Clinical Trial Update: Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria [Phase 2]

View source ↗

Summary

A Phase 2 clinical study is assessing the safety and efficacy of Polymyxin E2 methanesulfonate for injection for treating hospital-acquired pneumonia and ventil…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hospital-acquired Pneumonia
• Ventilator-associated Pneumonia

Drugs mentioned

• Polymyxin E2 Methanesulfonate for Injection (polymyxin E2 methanesulfonate)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Hospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial Pneumonia | Phase 2 | Status: NOT_YET_RECRUITING